000			02100 a2200613 4500
005			20250517055853.0
264		0	_c20160829
008			201608s 0 0 eng d
022			_a1551-4005
024	7		_a10.1080/15384101.2015.1090065 _2doi
040			_aNLM _beng _cNLM
100	1		_aJain, Rajul K
245	0	0	_aNovel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. _h[electronic resource]
260			_bCell cycle (Georgetown, Tex.) _c2015
300			_a3434-40 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Journal Article
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBortezomib _xadministration & dosage
650	0	4	_aComputer Simulation
650	0	4	_aDisease Progression
650	0	4	_aDisease-Free Survival
650	0	4	_aDrug Administration Schedule
650	0	4	_aFemale
650	0	4	_aG1 Phase Cell Cycle Checkpoints _xdrug effects
650	0	4	_aG2 Phase Cell Cycle Checkpoints _xdrug effects
650	0	4	_aHumans
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aMale
650	0	4	_aMaximum Tolerated Dose
650	0	4	_aMiddle Aged
650	0	4	_aModels, Biological
650	0	4	_aMolecular Targeted Therapy
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aS Phase Cell Cycle Checkpoints _xdrug effects
650	0	4	_aSirolimus _xadministration & dosage
650	0	4	_aTexas
650	0	4	_aTime Factors
650	0	4	_aTopotecan _xadministration & dosage
650	0	4	_aTreatment Outcome
650	0	4	_aYoung Adult
700	1		_aHong, David S
700	1		_aNaing, Aung
700	1		_aWheler, Jennifer
700	1		_aHelgason, Thorunn
700	1		_aShi, Nai-Yi
700	1		_aGad, Yash
700	1		_aKurzrock, Razelle
773	0		_tCell cycle (Georgetown, Tex.) _gvol. 14 _gno. 21 _gp. 3434-40
856	4	0	_uhttps://doi.org/10.1080/15384101.2015.1090065 _zAvailable from publisher's website
999			_c25354550 _d25354550